These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38812074)

  • 21. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
    Guo F; Letrent SP; Sharma A
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pooled Population Pharmacokinetic Analysis for Exploring Ciprofloxacin Pharmacokinetic Variability in Intensive Care Patients.
    Guo T; Abdulla A; Koch BCP; van Hasselt JGC; Endeman H; Schouten JA; Elbers PWG; Brüggemann RJM; van Hest RM;
    Clin Pharmacokinet; 2022 Jun; 61(6):869-879. PubMed ID: 35262847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pediatric Population Pharmacokinetic Modeling and Exposure-Response Analysis of Ambrisentan in Pulmonary Arterial Hypertension and Comparison With Adult Data.
    Okour M; Thapar MM; Farrell C; Lukas MA; Beghetti M; Beerahee M
    J Clin Pharmacol; 2023 May; 63(5):593-603. PubMed ID: 36579617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects.
    Plock N; Facius A; Hartmann L; Baumann S; Nave R
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):495-508. PubMed ID: 23611571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials.
    Suleiman AA; Minocha M; Khatri A; Pang Y; Othman AA
    Clin Pharmacokinet; 2019 Oct; 58(10):1309-1321. PubMed ID: 31054118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials.
    Xiang H; Liu L; Gao Y; Ahene A; Collins H
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):899-910. PubMed ID: 34383128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
    Humbert M; McLaughlin V; Gibbs JSR; Gomberg-Maitland M; Hoeper MM; Preston IR; Souza R; Waxman A; Escribano Subias P; Feldman J; Meyer G; Montani D; Olsson KM; Manimaran S; Barnes J; Linde PG; de Oliveira Pena J; Badesch DB;
    N Engl J Med; 2021 Apr; 384(13):1204-1215. PubMed ID: 33789009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.
    Humbert M; McLaughlin V; Gibbs JSR; Gomberg-Maitland M; Hoeper MM; Preston IR; Souza R; Waxman AB; Ghofrani HA; Escribano Subias P; Feldman J; Meyer G; Montani D; Olsson KM; Manimaran S; de Oliveira Pena J; Badesch DB
    Eur Respir J; 2023 Jan; 61(1):. PubMed ID: 36041750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pharmacokinetic comparison of anrukinzumab, an anti- IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients.
    Hua F; Ribbing J; Reinisch W; Cataldi F; Martin S
    Br J Clin Pharmacol; 2015 Jul; 80(1):101-9. PubMed ID: 25614144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Navigating the Sotatercept landscape: A meta-analysis of clinical outcomes.
    Nasrollahizadeh A; Soleimani H; Nasrollahizadeh A; Hashemi SM; Hosseini K
    Clin Cardiol; 2024 Jan; 47(1):e24173. PubMed ID: 37819149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus.
    Hoeben E; De Winter W; Neyens M; Devineni D; Vermeulen A; Dunne A
    Clin Pharmacokinet; 2016 Feb; 55(2):209-23. PubMed ID: 26293616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.
    Zheng B; Yu XQ; Greth W; Robbie GJ
    Br J Clin Pharmacol; 2016 May; 81(5):918-28. PubMed ID: 26659791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
    Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetics of subcutaneous C1-inhibitor for prevention of attacks in patients with hereditary angioedema.
    Pawaskar D; Tortorici MA; Zuraw B; Craig T; Cicardi M; Longhurst H; Li HH; Lumry WR; Martinez-Saguer I; Jacobs J; Bernstein JA; Riedl MA; Katelaris CH; Keith PK; Feussner A; Sidhu J
    Clin Exp Allergy; 2018 Oct; 48(10):1325-1332. PubMed ID: 29998524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pooled Population Pharmacokinetic Analyses of Venetoclax in Patients Across Indications and Healthy Subjects from Phase 1, 2, and 3 Clinical Trials.
    Gong JQX; Suleiman AA; Menon R; Deng R; Mensing S; Salem AH
    J Clin Pharmacol; 2023 Aug; 63(8):950-960. PubMed ID: 37055934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing.
    Yin A; Ettaieb MHT; Swen JJ; van Deun L; Kerkhofs TMA; van der Straaten RJHM; Corssmit EPM; Gelderblom H; Kerstens MN; Feelders RA; Eekhoff M; Timmers HJLM; D'Avolio A; Cusato J; Guchelaar HJ; Haak HR; Moes DJAR
    Clin Pharmacokinet; 2021 Jan; 60(1):89-102. PubMed ID: 32607875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population Pharmacokinetic Modeling of Cotadutide: A Dual Agonist Peptide of Glucagon-Like Peptide and Glucagon Receptors Administered to Participants with Type II Diabetes Mellitus, Chronic Kidney Disease, Obesity and Non-Alcoholic Steatohepatitis.
    Yu H; Åstrand M; Cheng J; Nitin K; Hamrén B; Khan AA
    Clin Pharmacokinet; 2024 Feb; 63(2):255-267. PubMed ID: 38236561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients.
    Trang M; Griffith DC; Bhavnani SM; Loutit JS; Dudley MN; Ambrose PG; Rubino CM
    Antimicrob Agents Chemother; 2021 Aug; 65(9):e0260620. PubMed ID: 34097490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How We Do It: Using Sotatercept in the Care of Patients with Pulmonary Arterial Hypertension.
    Preston IR; Lewis D; Gomberg-Maitland M
    Chest; 2024 Jul; ():. PubMed ID: 39004216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.